Expression of UTP23 gene in epithelial ovarian cancer paclitaxel resistant cells and its effect on paclitaxel resistance to chemotherapy

Abstract

Abstract:

AIM: To investigate the expression of UTP23 gene in epithelial ovarian cancer paclitaxel resistant cells and its effect on the resistance to paclitaxel chemotherapy. METHODS: The reverse transcriptase polymerase chain reaction (RT-PCR) and Western blot were used to detect the expression level of UTP23, P-gp, MDR1 mRNA in epithelial ovarian cancer paclitaxel resistant cells; specific UTP23-siRNA was used to transfect epithelial ovarian cancer paclitaxel resistant cells; the expression of UTP23 gene after transfection was detected by RT-PCR and Western blot method; the effect of UTP23-iRNA on the growth of epithelial ovarian cancer paclitaxel resistant cells and drug resistance were detected by MTT method. RESULTS:The expression level of UTP23 gene mRNA in the resistant group was significantly lower than that in the sensitive group (P<0.05); the expression levels of P-gp mRNA and MDR1 mRNA in the resistant group were significantly higher than those in the sensitive group (P<0.05); compared with the non transfection group and the negative control group, the levels of UTP23 mRNA in the transfection group were significantly increased (P<0.05); compared with the negative control group, there was no significant difference of the level of UTP23 mRNA and protein level in the non transfection group (P>0.05); compared with the non transfection group and the negative control group, the expression levels of P-gp mRNA and MDR1 mRNA were significantly decreased in the transfection group (P<0.05); compared with the negative control group, there was no significant difference of the expression level of P-gp and MDR1 in mRNA in the transfection group (P>0.05); Paclitaxel on UTP23-siRNA after transfection, the concentration of IC50 in epithelial ovarian cancer resistant cell in the transfection group was significantly higher than those of the non transfection group and negative control group (P<0.05). CONCLUSION:The expression level of UTP23 gene in epithelial ovarian cancer paclitaxel resistant cells is low; it may be involved in the resistance of paclitaxel cells to paclitaxel in epithelial ovarian cancer by indirectly regulating the expression of MDR1 and P-gp.

Key words: epithelial ovarian cancer, UTP23 gene, paclitaxel resistant cells, drug resistance

CLC Number:

TONG Yuehong, SHAO Mingjun, HU Min, HU Meixu, ZHANG Lin, ZHU Pengfei. Expression of UTP23 gene in epithelial ovarian cancer paclitaxel resistant cells and its effect on paclitaxel resistance to chemotherapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 654-658.

References

［1］杜雪莲, 王聪, 刘明,等. 紫杉醇加卡铂与吉西他滨为基础联合化疗序贯用药对降低上皮性卵巢癌复发的临床研究［J］. 中国实用妇科与产科杂志, 2015，31(1): 59-64.
［2］Lu J, Sun M, Ye K. Structural and functional analysis of Utp23, a yeast ribosome synthesis factor with degenerate PIN domain［J］. RNA, 2013, 19(12):1815-1824.
［3］王新宇. 卵巢癌干细胞样细胞与耐紫杉醇细胞的差异表达蛋白谱特征及其临床意义［D］. 浙江大学, 2014.
［4］叶俊良, 高杨. 上皮性卵巢癌复发的影响因素分析［J］. 安徽医学, 2015，36(2):167-170.
［5］李秀琴, 王欣彦. 上皮性卵巢癌精准治疗研究进展［J］. 中国实用妇科与产科杂志, 2016，32(8):810-813.
［6］顾卓荣, 邱丽华. Fn14在上皮性卵巢癌中的表达与化疗耐药及预后相关性研究［J］. 现代妇产科进展, 2016, 25(2):85-88.
［7］张瑾, 李红霞. 卵巢上皮癌组织中hMSH2的表达及其与化疗耐药的关系［J］. 肿瘤防治研究, 2015, 42(6):571-575.
［8］张春妤, 郭红燕, 韩劲松,等. 三磷酸腺苷结合盒转运蛋白G2、F2在卵巢上皮性癌组织中的表达与意义［J］. 中华妇产科杂志, 2014, 49(3):224-225.
［9］韦露薇, 李力. 上皮性卵巢癌多药耐药相关信号传导通路及其靶向药物研究进展［J］. 中国肿瘤临床, 2016, 43(9):396-399.
［10］李淑青, 陈亚萍. 卵巢癌对顺铂和紫杉醇耐药的分子机制［J］. 国际妇产科学杂志, 2016, 43(2):145-150.
［11］刘群, 李锐锐, 眭蕊,等. 紫杉醇耐药卵巢癌细胞系的建立及耐药机制研究［J］. 癌症进展, 2014, 12(2):199-204.
［12］张阔, 陈燕, 郭延霞. 靶向治疗在卵巢癌中的研究进展［J］. 河北联合大学学报(医学版), 2014,16(2):173-175.
［13］姬时宇, 胡毅. 白蛋白结合型紫杉醇治疗晚期原发性肝癌的效果观察［J］. 临床肝胆病杂志, 2016, 32(10):1911-1915.

[1]	LI Shan, LIU Yixin, REN Feifei, LI Xiangchen, ZHANG Zhiqing. Research progress of natural plant active ingredients in reversing tumor multidrug resistance by down-regulating P-gp [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 331-340.
[2]	LIU Jiajia, GAO Yan, ZHANG Yehui, WU Jing. Functions of CRABP2 in tumorigenesis and progression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 86-92.
[3]	DONG Wei, HUANG Xiaoying, XIE Bingbin, TANG Xilan, LI Hongming, QIU Yumei, ZHAO Guowei, LIANG Xinli. Effects of oxypeucedanin on the resistance of breast cancer MCF-7/DOX cells to doxorubicin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 260-266.
[4]	MENG Qiang, LIU Kexin. Research status and prospect of transporter-mediated drug-drug interactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 876-888.
[5]	YANG Hechun, SHI Daohua . Research progress of small molecule inhibitors that reverse tumor drug resistance by regulating tumor glucose metabolism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 836-840.
[6]	WEI Songchang, YANG Hongqi, ZHANG Hongjuan, SHI Xiaoli, REN Kaiwen. Correlation between the expression of RON protein and CXC chemokine receptor 4 protein and abiraterone resistance in patients with castration-resistant prostate cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 414-422.
[7]	JIN Le, JIANG Duochen, CHEN Hongxiao, LIU Su, CHEN Zhaolin, JU Jing. Quercetin reverses adriamycin resistance by activating GSK-3β/β-catenin pathways through GAS5 in breast cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1344-1351.
[8]	WANG Ziyuan, SUN Mingyu. Advances in research on long non-coding RNA in drug resistance of colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 796-802.
[9]	YANG Yanlang, LI Yan, WANG Lin. Distribution and drug resistance of bacterial pathogens in the infecting inpatients of department of nephrology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 203-208.
[10]	XU Weiping, ZHOU Weiying. Advances in the sensitization mechanism of chemotherapeutic drugs for bladder cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1060-1064.
[11]	FANG Chuanchuan, NI Guantai, JIN Lan, LIU Ji, LIU Xiaoqing, QIAO Chun, LUO Yonghong. Correlation between phosphorylation of PEA-15-Ser104 site and prognosis of epithelial ovarian cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 523-528.
[12]	WANG Xiaoli, LU Shuping, DAI Jiale. Role of MSX2 in melanoma cells for trametinib resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1147-1154.
[13]	FU Peishu, SUN Fengjun, FENG Wei, XIONG Lirong, LI Xiaoyu, XIA Peiyuan. Progress in drug therapy for multidrug-resistant Acinetobacter baumannii infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1181-1187.
[14]	LI Zhaoxia，WANG Rui，LI Aimin，LIU Youning. Study of the primary target and mutation position in nemonoxacin-resistant mutants of Staphlococcus aureus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 667-671.
[15]	YE Haizhu, CHEN Yajuan, ZHAO Wenying, LIU Xiaoping. Different expression of FoxO3/Keap1/Nrf2 pathway in tumor cells and drug resistant tumor cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 859-865.